Artigo Revisado por pares

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

2023; American Medical Association; Volume: 10; Issue: 2 Linguagem: Inglês

10.1001/jamaoncol.2023.5410

ISSN

2374-2445

Autores

Krishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, Alexander Arkhipov, Cumhur Tekin, Kan Li, Sarper Toker, Stephen J. O’Keefe, Domenica Lorusso,

Tópico(s)

Cervical Cancer and HPV Research

Resumo

The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown.

Referência(s)
Altmetric
PlumX